The Cooper Companies (COO)
(Real Time Quote from BATS)
$106.57 USD
+0.07 (0.07%)
Updated Sep 6, 2024 03:50 PM ET
After-Market: $106.55 -0.02 (-0.02%) 4:12 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.57 USD
+0.07 (0.07%)
Updated Sep 6, 2024 03:50 PM ET
After-Market: $106.55 -0.02 (-0.02%) 4:12 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
PDCO vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. COO: Which Stock Is the Better Value Option?
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for June 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.
Cooper Cos. (COO) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -29.11% and -10.02%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
Analysts Estimate Cooper Cos. (COO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to gain traction from its robustly performing CVI and CSI businesses.
Masimo SafetyNet to Help Clinicians Fight Coronavirus Better
by Zacks Equity Research
Masimo (MASI) announces the full market release of Masimo SafetyNet, which is a remote patient management solution that will help in the fight against the COVID-19 pandemic.
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its ARIES SARS-CoV-2 Assay, which will be used to rapidly detect the virus causing COVID-19.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.
BD Gets EUA for New Test to Combat the Coronavirus Crisis
by Zacks Equity Research
BD (BDX) partners with BioGX to introduce a new diagnostic test to help hospitals boost the capacity of quick, on-site testing of COVID-19.
Cooper Cos. (COO) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MCK vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Here's Why You Should Add Integer Holdings to Your Portfolio
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
BD Launches New Test to Help Combat the Coronavirus Outbreak
by Zacks Equity Research
BD (BDX), along with BioMedomics, launches a new point-of-care test to help fight the coronavirus outbreak.
Allscripts Offers Telehealth Support Amid Coronavirus Outbreak
by Zacks Equity Research
Allscripts (MDRX) offers simplified telehealth implementation to health systems through FollowMyHealth to provide telehealth visit capabilities to their patients quickly.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to gain traction from its multi-year strategic growth initiative and distribution solutions segment.
Why You Should Invest in Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its NxTAG CoV Extended Panel that will be used to detect the SARS-CoV-2 virus.
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.